Hims & Hers Health is growing up fast—and the market is making it earn every inch

Hims & Hers’ big question: are you a healthcare company or a hype company?

Hims & Hers Health has always understood the internet better than most healthcare brands. It sells sensitive-care categories—hair loss, sexual health, skincare, mental health—with the kind of clean design and low-friction checkout that feels closer to a premium DTC brand than a doctor’s office.

But on February 23, 2026, when the company reported fourth-quarter and full-year 2025 results, investors didn’t just grade the vibes. They graded the business. And the verdict was basically: we like the growth, we’re nervous about the “weight-loss era,” and we want to know what the adult version of Hims looks like.

What actually happened in earnings

In 2025, Hims & Hers reported revenue of $2.35 billion, up 59% year over year, with net income of $128.4 million and adjusted EBITDA of $318.0 million. Subscribers grew to over 2.5 million, up 13% year over year.

The fourth quarter showed the tension investors are focused on: revenue rose to $617.8 million (up 28% year over year), but gross margin slipped to 72% (from 77% a year earlier), and quarterly net income fell to $20.6 million (from $26.0 million). Free cash flow was -$2.6 million in Q4 2025, compared with $59.5 million a year earlier.

Then came the forward-looking part. For full-year 2026, Hims guided revenue to $2.7–$2.9 billion and adjusted EBITDA to $300–$375 million. In plain English: “We think we’ll keep growing, but we’re also spending to build what’s next.”

Why this is suddenly complicated: the GLP-1 spotlight

Hims didn’t become a household ticker because people discovered multivitamins. The weight-loss boom pulled the company into a bigger cultural conversation—one where demand is enormous, brand trust matters, and regulators pay attention.

In early February 2026, the company drew headlines after saying it would offer a cheaper, compounded version of a Wegovy-like weight-loss pill, prompting Novo Nordisk to threaten legal action. The broader context here is messy: compounded GLP-1s filled gaps when branded drugs were in shortage, but the U.S. regulator has signaled shortages are largely resolved—making “compounding at scale” a legal and reputational minefield.

So when Hims tells investors it’s investing and expanding, the market’s follow-up is immediate: expanding into what, exactly—and under what rules?

The real Hims story is distribution

Here’s the underrated part of Hims: it’s building a consumer healthcare distribution machine. Not just ads, but retention loops. Subscriptions. Personalization. Cross-selling from one condition to another. If that engine works, Hims doesn’t need every category to be a once-in-a-generation trend—it needs a portfolio of “quietly essential” products that keep people paying monthly.

That’s why the 2026 guidance matters. It frames Hims less like a single-product moment and more like a platform trying to scale responsibly. The platform pitch is: customers come for one thing, stay for many.

The bet investors are really making

The market isn’t asking Hims to stop being ambitious. It’s asking it to prove it can grow without constantly leaning on the most controversial, regulator-magnet category in its lineup.

If Hims can show, through 2026, that its core telehealth subscriptions and newer offerings can carry growth while margins stabilize, the story shifts from “internet pharmacy with a hot product” to “modern healthcare brand with durable recurring revenue.” That’s a very different identity—and a very different kind of investor base.